title: MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma.
abstract: MAGE proteins have been identified as potential specific targets for cancer vaccination. Although MAGE-6 and MAGE-12 were originally identified in malignant melanoma there are no studies reporting the frequency of expression of these antigens in this malignancy. These are of relevance particularly for MAGE-6 as recent studies have identified CTL activity against several epitopes. We have studied MAGE-1, -2, -3, -4, -6 and -12 gene expression using reverse transcription-polymerase chain reaction in 47 melanoma samples and 11 melanoma cell lines established from these tumours. The tumour samples expressed MAGE-12 (74%) and MAGE-6 (64%) mRNA at much higher frequencies than the other MAGE genes. MAGE-12 and MAGE-6 were expressed at the highest frequencies, relative to the other MAGE antigens, in early stage lesions. The frequency of expression of all the MAGE genes was found to be higher in samples from metastatic deposits compared to those from locoregional disease. The cell lines all expressed the same or more MAGE antigens than the tumours from which they were derived. In only one cell line was expression of a MAGE antigen lost. Certain recurring patterns of MAGE expression were observed in the tumour samples. MAGE-6 and/or -12 expression were detected in all of those 26 tumour samples that were positive for one or more of MAGE-1, -2, -3 and -4. Twenty of these 26 samples expressed both antigens. These findings suggest that protocols targeting MAGE-12 and -6 would permit many more patients to be included into clinical cancer vaccination trials.
authors.affiliation: Ludwig Institute for Cancer Research and the Medical Oncology Department of the Austin and Repatriation Medical Centre, Heidelberg, Australia.
authors.forename: P
authors.initials: P
authors.lastname: Gibbs
authors.forename: A M
authors.initials: AM
authors.lastname: Hutchins
authors.forename: K T
authors.initials: KT
authors.lastname: Dorian
authors.forename: H A
authors.initials: HA
authors.lastname: Vaughan
authors.forename: I D
authors.initials: ID
authors.lastname: Davis
authors.forename: M
authors.initials: M
authors.lastname: Silvapulle
authors.forename: J S
authors.initials: JS
authors.lastname: Cebon
mesh_terms: D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000096:biosynthesis / Q000235:genetics*; D017931:DNA Primers / Q000737:chemistry; D015870:Gene Expression; D006801:Humans; D008545:Melanoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics*; D012333:RNA, Messenger / Q000096:biosynthesis*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017422:Sequence Analysis, DNA; D012878:Skin Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D014407:Tumor Cells, Cultured
chemical_list: D000951:Antigens, Neoplasm; D017931:DNA Primers; C409589:MAGEA12 protein, human; C095203:MAGEA6 protein, human; D009363:Neoplasm Proteins; D012333:RNA, Messenger